Clinical Trial

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-28
critical Recruitment opened 2026-04-17
Trial Details
NCT Number NCT07428759
Lead Sponsor GlaxoSmithKline
Conditions Pneumonia, Bacterial
Enrollment 121 participants
Start Date 2026-03-10
Primary Completion 2026-12-09 (estimated)
Study Completion 2026-12-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-27